Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157060 | 1.00 | GPR119 (0.56) | GPR119USP30GRM5HPGDSPOLB | |
| SCHEMBL18115645 | 0.84 | GPR119 (0.59) | GPR119USP30HPGDS | |
| SCHEMBL21775442 | 0.83 | GPR119 (0.50) | GPR119USP30POLBJAK2JAK1 | |
| SCHEMBL21748690 | 0.83 | GPR119 (0.50) | GPR119USP30POLBJAK2JAK1 | |
| SCHEMBL21748693 | 0.83 | GPR119 (0.50) | GPR119USP30POLBJAK2JAK1 | |
| SCHEMBL30783205 | 0.83 | GPR119 (0.50) | GPR119USP30POLBJAK2JAK1 | |
| SCHEMBL5923783 | 0.82 | RORC (0.57) | GPR119USP30HPGDSUSP7JAK2 | |
| SCHEMBL4489075 | 0.82 | RORC (0.57) | GPR119USP30HPGDSUSP7JAK2 | |
| SCHEMBL4080053 | 0.82 | GPR119 (0.65) | GPR119USP30HPGDSPOLBMMP13 | |
| SCHEMBL4484794 | 0.82 | RORC (0.57) | GPR119USP30HPGDSUSP7JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | GPR119 522/4885USP30 3958/4885GRM5 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.